Mostrar el registro sencillo del ítem
dc.contributor.author | Gasent Blesa, J. M. | es_ES |
dc.contributor.author | Alberola Candel, V. | es_ES |
dc.contributor.author | Giner Marco, V. | es_ES |
dc.contributor.author | Giner-Bosch, Vicent | es_ES |
dc.contributor.author | Provencio Pulla, M. | es_ES |
dc.contributor.author | Laforga Canales, J. B. | es_ES |
dc.date.accessioned | 2018-02-24T05:18:01Z | |
dc.date.available | 2018-02-24T05:18:01Z | |
dc.date.issued | 2010 | es_ES |
dc.identifier.issn | 0923-7534 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/98412 | |
dc.language | Inglés | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.relation.ispartof | Annals of Oncology | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject.classification | ESTADISTICA E INVESTIGACION OPERATIVA | es_ES |
dc.title | Experience with fulvestrant acetate in castration-resistant prostate cancer patients | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1093/annonc/mdq010 | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Departamento de Estadística e Investigación Operativa Aplicadas y Calidad - Departament d'Estadística i Investigació Operativa Aplicades i Qualitat | es_ES |
dc.description.bibliographicCitation | Gasent Blesa, JM.; Alberola Candel, V.; Giner Marco, V.; Giner-Bosch, V.; Provencio Pulla, M.; Laforga Canales, JB. (2010). Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Annals of Oncology. 21(5):1131-1132. doi:10.1093/annonc/mdq010 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1093/annonc/mdq010 | es_ES |
dc.description.upvformatpinicio | 1131 | es_ES |
dc.description.upvformatpfin | 1132 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 21 | es_ES |
dc.description.issue | 5 | es_ES |
dc.relation.pasarela | S\38137 | es_ES |
dc.description.references | Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990). Inhibition of estrogen receptor-DNA binding by the «pure» antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences, 87(17), 6883-6887. doi:10.1073/pnas.87.17.6883 | es_ES |
dc.description.references | Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992). Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences, 89(9), 4037-4041. doi:10.1073/pnas.89.9.4037 | es_ES |
dc.description.references | Leav, I., Lau, K.-M., Adams, J. Y., McNeal, J. E., Taplin, M.-E., Wang, J., … Ho, S.-M. (2001). Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma. The American Journal of Pathology, 159(1), 79-92. doi:10.1016/s0002-9440(10)61676-8 | es_ES |
dc.description.references | Bhattacharyya, R. S. (2006). Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Molecular Cancer Therapeutics, 5(6), 1539-1549. doi:10.1158/1535-7163.mct-06-0065 | es_ES |
dc.description.references | Galsky, M. D., Simon, K., Sonpavde, G., Hutson, T. E., Fleming, M., Kondagunta, G. V., & Berry, W. (2009). Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Annals of Oncology, 20(5), 965-966. doi:10.1093/annonc/mdp199 | es_ES |
dc.description.references | Serrate, C., Loriot, Y., De La Motte Rouge, T., Gross-Goupil, M., Massard, C., Escudier, B., … Fizazi, K. (2009). Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Annals of Oncology, 20(5), 965-965. doi:10.1093/annonc/mdp112 | es_ES |
dc.description.references | Chadha, M. K., Ashraf, U., Lawrence, D., Tian, L., Levine, E., Silliman, C., … Trump, D. L. (2008). Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer. The Prostate, 68(13), 1461-1466. doi:10.1002/pros.20813 | es_ES |